UNSPSC 51321701: Atorvastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C33H35FN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A0JWA85V8F, chemically known as 1h-pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (r-(r*,r*))- but generally known as atorvastatin, which bears US NIH Compound Identifier 60823. Atorvastatin most often comes in base, calcium, and lactone forms.

UNSPSC 51321701 Atorvastatin is a Commodity code covering specific statin medications procured by state and local health systems, fire rescue services, and pharmacy benefit programs. State and local governments buy this code primarily as part of broader emergency medical supplies, formulary management, and direct-to-manufacturer pharmacy initiatives. The City of Tampa Fire Rescue, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance represent the range of issuing bodies — municipal emergency services, state health agencies, and multistate cooperative purchasing vehicles — that source pharmaceuticals under this and related product codes. The work involves supplying atorvastatin as one component within larger medication contracts that emphasize regulatory compliance, expiration-date management, safety documentation, and delivery-speed commitments.

Recent activity spans Florida, Texas, and a multistate cooperative covering participating jurisdictions including Oregon and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (response due April 8, 2026, estimated contract value $40,000) requiring sealed bids for four medication line items including labetalol, epinephrine, adenosine, and diltiazem for Tampa Fire Rescue in Hillsborough County, with a one-year term and optional renewals, supported by a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission released RFI HHS0017013 (response deadline April 3, 2026) seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, signaling potential future procurement of pharmaceuticals outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 (response due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with evaluations weighted 75 percent on price competitiveness and effective date July 1, 2026.